From the Blood Journals

From the Blood Journals

Research from the Blood family of journals: Blood and Blood Advances

WIB_icon

Rates of Myeloid Neoplasms in Patients With Unexplained Cytopenias

Patients with unexplained cytopenias may never receive a definitive diagnosis, or may eventually be classified as having myelodysplastic syndromes (MDS, a myeloproliferative neoplasm ...
WIB_icon

Enoxaparin Increases Risk of Intracranial Hemorrhage in Patients With Glioma

Venous thromboembolism occurs in approximately one-third of patients with glioma, but the decision to treat patients with anticoagulation is complicated by the risk for...
WIB_icon

CD19-Directed CAR T-Cell Therapy Associated With High Rates of MRD Negativity in Young Patients...

Though CD19-directed chimeric antigen receptor (CAR) T-cell therapies have shown great promise for the treatment of hematologic malignancies, the possibility of routinely bringing these...
WIB_icon

Selinexor Induces Response in Patients With Various Subtypes of Non-Hodgkin Lymphoma and Chronic Lymphocytic...

The heterogeneity of the various subtypes of non-Hodgkin lymphomas (NHLs) necessitates the development of specific therapies that address fundamental mechanisms that are dysregulated in...
WIB_icon

Predicting Response and Prognosis With Midostaurin in Advanced Systemic Mastocytosis

In April 2017, the U.S. Food and Drug Administration approved the multitargeted KIT inhibitor for the treatment of adult patients with FLT3-positive, newly diagnosed...
WIB_icon

Pembrolizumab Prompts Response in Patients With Richter’s Transformation

Patients with chronic lymphocytic leukemia (CLL) who progress early during ibrutinib treatment often develop Richter’s transformation (RT), which is associated with an average survival...
WIB_icon

Predicting Survival Outcomes for Children With Down Syndrome and AML or MDS

Children with Down syndrome (DS) have a higher risk of developing acute lymphocytic leukemia (ALL) and acute myeloid leukemia (AML) than those without DS....

Long-Term Study Highlights Limitations of Current TTP Diagnostic Methods

For the past two decades, ADAMTS13 activity has been the backbone of diagnosis for thrombotic thrombocytopenic purpura (TTP); however, a long-term registry study published...
WIB_icon

Weighing the Risks and Benefits of Nivolumab in Patients With Hodgkin Lymphoma Undergoing AlloHCT

For patients with Hodgkin lymphoma (HL), allogeneic hematopoietic cell transplantation (alloHCT) can induce long-term disease control; however, relapse is common and rates of 3-year...
WIB_icon

Pembrolizumab Induces Remission in Small Cohort of Patients With Natural Killer/T-Cell Lymphomas

For the 20 to 40 percent of patients with natural killer (NK)/T-cell lymphomas who do not respond to regimens such as SMILE (dexamethasone, methotrexate,...
Advertisement

Current Issue

July 2017, Volume 3, Issue 8

This issue features an interview with the FDA's Richard Pazdur, highlights from the 2017 ASCO Annual Meeting, a debate about minimal residual disease in myeloma, and more.